위마비 치료제 시장 : 약물 종류별, 질환별, 투여 경로별, 약물 유형별, 유통 채널별, 세계 예측

Global Gastroparesis Drugs Market will register over 5% CAGR from 2024 to 2032. The market is expanding due to significant investments by pharmaceutical companies in research and development. This investment aims to meet the unmet medical needs of patients suffering from gastroparesis, a condition characterized by delayed stomach emptying.

With advancements in drug development and therapeutic strategies, pharmaceutical firms are focusing on innovative treatments to improve patient outcomes. These efforts not only usher market growth but also enhance the availability of effective medications for managing gastroparesis, catering to the increasing demand driven by rising disease prevalence and diagnostic advancements globally.

The overall Gastroparesis Drugs industry is classified based on drug class, disease type, route of administration, drug type, distribution channel, and region.

The pro kinetic agents segment in the gastroparesis drugs market will maintain a notable CAGR between 2024 and 2032, owing to their effectiveness in enhancing stomach motility, a critical therapeutic target for managing gastroparesis symptoms. pro kinetic agents stimulate gastrointestinal contractions, thus promoting more timely stomach emptying and alleviating symptoms such as nausea, vomiting, and bloating. As pharmaceutical companies focus on developing and improving these agents, patients and healthcare providers increasingly rely on them for symptom relief and improved quality of life. This targeted approach underscores the growing demand for specialized treatments within the market, driving advancements in pro-kinetic therapies.

By 2032, the idiopathic gastroparesis sector will secure a significant gastroparesis drugs market share because of its status as the most common form of the condition, where the exact cause is unknown. As awareness and diagnosis improve, more patients are identified with idiopathic gastroparesis, leading to an increased demand for effective treatment options to manage its chronic symptoms. Pharmaceutical companies are therefore focusing on developing therapies that target the underlying mechanisms of idiopathic gastroparesis, such as gastric dysmotility and impaired stomach emptying. This emphasis reflects a growing need for tailored treatments that address the specific challenges of this patient population.

Between 2024 and 2032, the North America gastroparesis drugs market will exhibit a strong CAGR. A higher prevalence of gastroparesis among the population is driven partly by lifestyle factors and an aging demographic. Additionally, advanced healthcare infrastructure and robust diagnostic capabilities in the region ensure early detection and treatment initiation, boosting demand. Pharmaceutical companies in North America are also at the forefront of research and development, continually innovating to meet the evolving needs of patients. These dynamics collectively contribute to the market growth in North America, making it a pivotal region for market expansion.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising incidence of gastroparesis
    • 3.2.1.2 Growing patient preference for non-invasive treatment
    • 3.2.1.3 Rising awareness and diagnosis rate
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Availability of limited treatment options
    • 3.2.2.2 Regulatory challenges
• 3.3 Growth potential analysis
• 3.4 Pipeline analysis
• 3.5 Regulatory landscape
• 3.6 Future market trends
• 3.7 Porter's analysis
• 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Company positioning matrix
• 4.6 Strategic dashboard

Chapter 5 Market Estimates and Forecast, By Drug Class, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Prokinetic agents
• 5.3 Antiemetic drugs
• 5.4 Proton pump inhibitors
• 5.5 Other drug classes

Chapter 6 Market Estimates and Forecast, By Disease Type, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Diabetes gastroparesis
• 6.3 Idiopathic gastroparesis
• 6.4 Post-surgical gastroparesis

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Oral
• 7.3 Injectable
• 7.4 Other routes of administration

Chapter 8 Market Estimates and Forecast, By Drug Type, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 OTC drugs
• 8.3 Prescription drugs

Chapter 9 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 Hospital pharmacies
• 9.3 Retail pharmacies
• 9.4 Online pharmacies

Chapter 10 Market Estimates and Forecast, By Region, 2021- 2032 ($ Mn)

• 10.1 Key trends
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 France
  • 10.3.4 Spain
  • 10.3.5 Italy
  • 10.3.6 The Netherlands
  • 10.3.7 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 Japan
  • 10.4.2 China
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 South Korea
  • 10.4.6 Rest of Asia Pacific
• 10.5 Latin America
  • 10.5.1 Brazil
  • 10.5.2 Mexico
  • 10.5.3 Rest of Latin America
• 10.6 Middle East and Africa
  • 10.6.1 South Africa
  • 10.6.2 Saudi Arabia
  • 10.6.3 UAE
  • 10.6.4 Rest of Middle East and Africa

Chapter 11 Company Profiles

• 11.1 Abbott Laboratories
• 11.2 AbbVie Inc,
• 11.3 AstraZeneca PLC
• 11.4 Bayer AG
• 11.5 Cipla Ltd.
• 11.6 Evoke Pharma
• 11.7 Pfizer Inc.
• 11.8 Salix Pharmaceuticals
• 11.9 Takeda Pharmaceutical Inc.
• 11.10 Teva Pharmaceutical Inc.